Prognostic Implications of Long-Chain Acylcarnitines in Heart Failure and Reversibility With Mechanical Circulatory Support
Ahmad T, Kelly JP, McGarrah RW, Hellkamp AS, Fiuzat M, Testani JM, Wang TS, Verma A, Samsky MD, Donahue MP, Ilkayeva OR, Bowles DE, Patel CB, Milano CA, Rogers JG, Felker GM, O’Connor C, Shah SH, Kraus WE. Prognostic Implications of Long-Chain Acylcarnitines in Heart Failure and Reversibility With Mechanical Circulatory Support. Journal Of The American College Of Cardiology 2016, 67: 291-299. PMID: 26796394, PMCID: PMC5429585, DOI: 10.1016/j.jacc.2015.10.079.Peer-Reviewed Original ResearchMeSH KeywordsAgedCarnitineDisease ProgressionEnergy MetabolismExercise TherapyFemaleHeart Failure, SystolicHeart-Assist DevicesHospital MortalityHumansMaleMass SpectrometryMiddle AgedNorth CarolinaOutcome Assessment, Health CarePrognosisReproducibility of ResultsSeverity of Illness IndexStatistics as TopicConceptsEnd-stage heart failureSystolic heart failureHeart failureMechanical circulatory supportHF patientsClinical outcomesCirculatory supportEnd-stage systolic heart failureChronic systolic HF patientsLeft ventricular assist device placementLong-term mechanical circulatory supportVentricular assist device placementPeak VO2 levelsChronic HF patientsSystolic HF patientsAdverse clinical outcomesClinical trial outcomesLong-chain acylcarnitinesAssociations of metabolitesFrozen plasma samplesMechanical circulatoryCardiovascular deathCause hospitalizationCause mortalityLVAD group